GB1573002A - Antiviral agent - Google Patents
Antiviral agent Download PDFInfo
- Publication number
- GB1573002A GB1573002A GB51415/76A GB5141576A GB1573002A GB 1573002 A GB1573002 A GB 1573002A GB 51415/76 A GB51415/76 A GB 51415/76A GB 5141576 A GB5141576 A GB 5141576A GB 1573002 A GB1573002 A GB 1573002A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- mice
- viruses
- tungsto
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003443 antiviral agent Substances 0.000 title description 3
- 241000700605 Viruses Species 0.000 claims description 101
- 238000011282 treatment Methods 0.000 claims description 43
- 208000032839 leukemia Diseases 0.000 claims description 27
- 102000014150 Interferons Human genes 0.000 claims description 26
- 108010050904 Interferons Proteins 0.000 claims description 26
- 229940079322 interferon Drugs 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 230000009385 viral infection Effects 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241000430519 Human rhinovirus sp. Species 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 49
- 238000007912 intraperitoneal administration Methods 0.000 description 37
- 239000000047 product Substances 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 230000000840 anti-viral effect Effects 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 238000011081 inoculation Methods 0.000 description 15
- 241001529936 Murinae Species 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- 239000005723 virus inoculator Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 8
- 229910052721 tungsten Inorganic materials 0.000 description 8
- 239000010937 tungsten Substances 0.000 description 8
- 241000709661 Enterovirus Species 0.000 description 7
- 150000003863 ammonium salts Chemical class 0.000 description 7
- 229910052787 antimony Inorganic materials 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 208000009889 Herpes Simplex Diseases 0.000 description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- VFBJEDFCUUCMBQ-UHFFFAOYSA-O azanium;sodium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[Na+].[Sb+3].[W] VFBJEDFCUUCMBQ-UHFFFAOYSA-O 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010041660 Splenomegaly Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000012429 reaction media Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229910017917 NH4 Cl Inorganic materials 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- FAPDDOBMIUGHIN-UHFFFAOYSA-K antimony trichloride Chemical compound Cl[Sb](Cl)Cl FAPDDOBMIUGHIN-UHFFFAOYSA-K 0.000 description 3
- 238000009109 curative therapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002122 leukaemogenic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 239000002253 acid Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000526 Experimental Leukemia Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000710130 Human rhinovirus 1A Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- WATWJIUSRGPENY-AKLPVKDBSA-N antimony-125 Chemical compound [125Sb] WATWJIUSRGPENY-AKLPVKDBSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- JVUIPFRSLYDCCX-UHFFFAOYSA-O azanium;antimony(3+);oxygen(2-);tungsten Chemical compound [NH4+].[O-2].[O-2].[O-2].[O-2].[O-2].[Sb+3].[W] JVUIPFRSLYDCCX-UHFFFAOYSA-O 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical class Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000006491 negative regulation of transport Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 1
- -1 tungsten ions Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G41/00—Compounds of tungsten
- C01G41/006—Compounds containing tungsten, with or without oxygen or hydrogen, and containing two or more other elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/82—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by IR- or Raman-data
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/60—Optical properties, e.g. expressed in CIELAB-values
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63941375A | 1975-12-10 | 1975-12-10 | |
| FR7605084A FR2334366A2 (fr) | 1975-12-10 | 1976-02-24 | Application a titre d'agents antiviraux de composes d'heteropolyanions contenant du tungstene combine a de l'antimoine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1573002A true GB1573002A (en) | 1980-08-13 |
Family
ID=26219311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB51415/76A Expired GB1573002A (en) | 1975-12-10 | 1976-12-09 | Antiviral agent |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5294431A (enExample) |
| GB (1) | GB1573002A (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629191B2 (ja) * | 1984-09-04 | 1994-04-20 | 株式会社ポリトロニクス | 抗腫瘍剤、抗ウィルス剤 |
| DE3542165A1 (de) * | 1984-12-03 | 1986-07-10 | Centre National De La Recherche Scientifique (C.N.R.S.), Paris | Medikament zur behandlung des syndroms der erworbenen immunschwaeche (aids) und entsprechende pharmazeutische zusammensetzungen |
| JP2707252B2 (ja) * | 1987-08-03 | 1998-01-28 | 利博 山瀬 | 抗ウィルス剤 |
-
1976
- 1976-12-09 GB GB51415/76A patent/GB1573002A/en not_active Expired
- 1976-12-10 JP JP14789976A patent/JPS5294431A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6120525B2 (enExample) | 1986-05-22 |
| JPS5294431A (en) | 1977-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4547369A (en) | Antiviral agent | |
| Jasmin et al. | In vivo inhibition of murine leukemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimoniate | |
| US4349538A (en) | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid | |
| US4473581A (en) | Organogermanium induction of interferon production | |
| Forssberg et al. | Modification of the X-irradiation syndrome by lycopene | |
| US3852334A (en) | Substituted carbazic acid esters | |
| US4024241A (en) | Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid | |
| Hilleman | Double-stranded RNAs (poly I: C) in the prevention of viral infections | |
| CH616432A5 (enExample) | ||
| EP0390365A1 (en) | Improvements in chemical compounds | |
| US4871540A (en) | Process for producing a biologically active substance and compositions containing the same | |
| JPS61165336A (ja) | 抗ウイルス特性を有する薬剤組成物 | |
| Hamilton et al. | Inhibition of herpes simplex virus by synthetic double-stranded RNA (polyriboadenylic and polyribouridylic acids and polyriboinosinic and polyribocytidylic acids) | |
| JPS6120525B2 (enExample) | ||
| US5932621A (en) | Methods of using ajoene for the treatment of tumors | |
| US5051414A (en) | Inhibition of HIV and other retroviruses by polyoxoanions | |
| US4759929A (en) | Novel treatment | |
| DE3885090T2 (de) | Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil. | |
| US5948821A (en) | Methods of using ajoene | |
| US5093327A (en) | Inhibition of HIV and other retroviruses by polyoxoanions | |
| US4223109A (en) | Calcium salts of divinyl ether--maleic anhydride copolymer | |
| JPS6163619A (ja) | 抗腫瘍剤、抗ウィルス剤 | |
| IE910512A1 (en) | Improvements in chemical compounds | |
| EP1338281B1 (en) | Method for producing an immunotropic antiviral preparation | |
| US3238104A (en) | Reabsorbable aescin composition and method of making |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] |